The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.
 
Cornelis J. A. Punt
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Nordic Bioscience; Roche
 
Lieke H Simkens
No Relationships to Disclose
 
Johan Van Rooijen
No Relationships to Disclose
 
Agnes W Van de Wouw
Employment - Sanofi (I)
Research Funding - Sanofi (Inst)
 
Olaf Loosveld
Travel, Accommodations, Expenses - Merck
 
Geert-Jan Creemers
No Relationships to Disclose
 
Mathijs P Hendriks
No Relationships to Disclose
 
Maartje Los
No Relationships to Disclose
 
Robbert Jeroen Van Alphen
Consulting or Advisory Role - Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Marco Polee
No Relationships to Disclose
 
Erik W Muller
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Pfizer
 
Ankie Van Der Velden
No Relationships to Disclose
 
Thymen Van Voorthuizen
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer; Roche
 
Miriam Koopman
Consulting or Advisory Role - Bayer; Merck; Roche; SERVIER
Research Funding - Amgen (Inst); Bayer (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
Linda Mol
No Relationships to Disclose
 
Johannes J Kwakman
No Relationships to Disclose
 
Erik D. van Werkhoven
No Relationships to Disclose